+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 0 - 8Years
All Genders
ID06679634

Phase II Expanded Access Study of Episcleral Topotecan Chemoplaque for Treating Advanced or Recurrent Retinoblastoma in Children Under 8 Years

Led by Targeted Therapy Technologies, LLC · Updated on 2026-05-22

30

Participants Needed

2

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating treatment options for children with advanced or recurrent retinoblastoma, a type of eye cancer. This study focuses on assessing the safety, optimal dose, and effectiveness of a chemoplaque called Episcleral Topotecan. The goal is to explore whether this treatment can help save eyes affected by retinoblastoma, especially in cases where conventional treatments have failed or eye removal is typically recommended. The treatment involves surgically placing a chemoplaque under the surface lining of the eye during an exam under anesthesia. This device releases chemotherapy medication continuously for 8 weeks and is attached to the eyes outer layer using tissue adhesive. Participants will have the chemoplaque removed on day 56. Eye exams under anesthesia will be conducted on days 0, 28, 56, and 84 to monitor progress and safety. During the study, blood tests will be done periodically to check blood health and monitor any medication side effects. The study will follow participants until day 84 when treatment ends. Researchers will measure safety by tracking the number and severity of treatment-related side effects and evaluate the treatments effect on the tumor. Overall, participants will undergo repeated eye exams, blood work, and careful monitoring throughout the 12-week period.

CONDITIONS

Brief Title

Retinoblastoma Phase II Expanded Access Clinical Trial

Research Team

B

Brian Marr, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here